Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1977 1
1978 2
1979 2
1980 1
1981 1
1983 2
1985 1
1986 4
1987 2
1988 4
1989 4
1990 3
1991 4
1992 2
1993 4
1994 2
1995 9
1996 2
1997 5
1998 8
1999 9
2000 8
2001 12
2002 6
2003 6
2004 3
2005 6
2006 7
2007 11
2008 6
2009 7
2010 5
2011 6
2012 5
2013 7
2014 6
2015 4
2016 5
2017 8
2018 5
2019 3
2020 4
2021 2
2022 1
2023 4
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Among authors: shuler cl. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Among authors: shuler cl. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Sister chromatid exchanges.
Latt SA, Schreck RR, Loveday KS, Dougherty CP, Shuler CF. Latt SA, et al. Among authors: shuler cf. Adv Hum Genet. 1980;10:267-331. doi: 10.1007/978-1-4615-8288-5_4. Adv Hum Genet. 1980. PMID: 6156589 Review. No abstract available.
Terminology.
Kumar SK, Sedghizadeh PP, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Silverman S. Kumar SK, et al. Among authors: shuler cf. J Am Dent Assoc. 2012 Jan;143(1):12; author reply 12-3. doi: 10.14219/jada.archive.2012.0003. J Am Dent Assoc. 2012. PMID: 22207659 No abstract available.
Multicentric peripheral ossifying fibroma.
Kumar SK, Ram S, Jorgensen MG, Shuler CF, Sedghizadeh PP. Kumar SK, et al. Among authors: shuler cf. J Oral Sci. 2006 Dec;48(4):239-43. doi: 10.2334/josnusd.48.239. J Oral Sci. 2006. PMID: 17220623 Free article.
204 results